Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

WILMINGTON, DE — AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an add-on maintenance treatment for adults and adolescents ...

Common colds inflame nasal lining. Early in infections itching and tickle frequently precede runny nose and congestion, ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

TUESDAY, Oct. 28, 2025 (HealthDay News) -- The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE ...

Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of ...

Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...

Tech giant Apple is proof of how far high-quality products and strong brand loyalty can go. It first became the world's most valuable company on Aug. 9, 2011, 15 days before Steve Jobs resigned as CEO ...